Dosing Schedules That Match the Evidence The schedules below follow the BNF and standard UK haematology guidance
The original clinical development, by the Canadian biotech ConjuChem, was discontinued, and there is no validated disease endpoint for either version
Adoption of these agents was underwhelming, however ( ) and tirzepatide (Zepbound ), approved for the treatment of obesity in 2021 and 2024, respectively, produced corresponding mean weight loss of 17% and 23% in clinical trials of subjects with obesity, but without T2D ( It is not a coincidence that AOMs are demonstrating progressively superior effectiveness
Rewind Wellness & Aesthetics offers peptide treatments for weight loss
These peptides can naturally occur in the body or be synthesized in a lab
Using this mechanism, we obtained EHR data from 909 participants with a recorded GLP1 medication prescription (Supplementary Table 5)